What is Celularity?
Celularity Inc. is a regenerative and cellular medicines company dedicated to addressing aging-related and degenerative diseases. The company's core focus lies in the development of off-the-shelf placental-derived allogeneic cell therapy product candidates. These candidates, including mesenchymal-like adherent stromal cells, are being investigated for conditions such as diabetic foot ulcer and Crohn's disease. Celularity operates across three key segments: Cell Therapy, Degenerative Disease, and BioBanking, with therapeutic programs like PDA-001 for autoimmune and degenerative diseases, and PDA-002 for facioscapulohumeral muscular dystrophy.
How much funding has Celularity raised?
Celularity has raised a total of $285.1M across 6 funding rounds:
Unspecified
$250M
Multiple Rounds
$21.8M
Other Financing Round
$13.3M
Unspecified (2018): $250M with participation from Genting Berhad, United Therapeutics, Human Longevity, Heritage Group, Sorrento Therapeutics, Celgene, the Dreyfus Family Office, and Section 32
Debt (2025): $6.8M, investors not publicly disclosed
Private Equity (2025): $1M, investors not publicly disclosed
Private Equity (2025): $2M, investors not publicly disclosed
Debt (2025): $12M, investors not publicly disclosed
Other Financing Round (2026): $13.3M with participation from NEXGEL
Key Investors in Celularity
Genting Berhad
Genting Group is a diversified conglomerate with interests in hospitality, gaming, and entertainment, suggesting a strategic investment in a company with broad healthcare applications.
United Therapeutics
United Therapeutics is a biotechnology company focused on developing innovative treatments for life-threatening pulmonary and rare diseases, aligning with Celularity's focus on regenerative medicine.
Section 32
Section 32 is a venture capital firm specializing in cutting-edge technology and healthcare investments, indicating a belief in Celularity's innovative approach to cellular therapies.
What's next for Celularity?
The substantial enterprise-level funding and recent strategic investment position Celularity for significant growth and advancement in its clinical programs. This capital infusion is expected to accelerate the development and commercialization of its innovative cell therapy candidates. The company's focus on addressing unmet needs in degenerative diseases and aging-related conditions, coupled with its robust financing, suggests a strategic push towards market leadership and the scaling of its therapeutic offerings. Future developments will likely center on clinical trial progress and potential market approvals.
See full Celularity company page
